EF
DNLI icon

Empowered Funds’s Denali Therapeutics DNLI Stock Holding History

Empowered Funds’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Sell
14,428
-1,359
-9% -$27.9K ﹤0.01% 1789
2026
Q1 		$303K Buy
15,787
+4,462
+39% +$88.8K ﹤0.01% 1821
2025
Q4 		$187K Buy
11,325
+288
+3% +$4.86K ﹤0.01% 943
2025
Q3 		$160K Sell
11,037
-3,783
-26% -$54.4K ﹤0.01% 1750
2025
Q2 		$207K Sell
14,820
-5,819
-28% -$81.9K ﹤0.01% 1634
2025
Q1 		$281K Buy
20,639
+2,052
+11% +$39.3K ﹤0.01% 1427
2024
Q4 		$379K Buy
+18,587
New +$476K 0.01% 1280

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Empowered Funds's DNLI Position: Q2 2026 in Review

Empowered Funds reduced its Denali Therapeutics (DNLI) stake by 8.6% in Q2 2026, selling an estimated $27.9K and leaving 14,428 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #1789.

Empowered Funds first reported a position in DNLI in Q4 2024 and has held it in 7 quarters since. The position peaked at $379K in Q4 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Empowered Funds held 14,428 shares of Denali Therapeutics worth $371K as of Q2 2026.
  • Empowered Funds sold 1,359 Denali Therapeutics shares in Q2 2026, an estimated $27.9K.
  • Denali Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1789 holding.
  • Empowered Funds first reported a position in Denali Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Empowered Funds's Denali Therapeutics position peaked at $379K in Q4 2024.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.